Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 2

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
,000,000  
     20,336,996  
     —  
     — 
  
    Basic and diluted net income (loss) per redeemable ordinary share 
    $0.07  
    $0.19  
    $—  
    $— 
  
    Weighted average non-redeemable ordinary shares outstanding (1)(2) 
     10,517,143  
     10,211,868  
     8,571,429  
     8,571,429 
  
    Basic net income (loss) per non-redeemable ordinary share 
    $0.07  
    $0.19  
    $(0.02) 
    $(0.02)
  
    Weighted average non-redeemable ordinary shares outstanding (1)(2) 
     10,517,143  
     10,453,407  
     8,571,429  
     8,571,429 
  
    Diluted net income (loss) per non-redeemable ordinary share 
    $0.07  
    $0.19  
    $(0.02) 
    $(0.02)

  (1) Includes an aggregate of up to 1,285,714 ordinary shares subject to surrender and forfeiture if the over-allotment option were not exercised in full by the underwriters (Note 5). In February 2025, the over-allotment option was exercised by the underwriters and these shares are no longer subject to forfeiture (Note 6).  (2) On November 6, 2024, the Sponsor surrendered and forfeited 12,503,968 ordinary shares to the Company for no consideration, following which the Sponsor held 9,857,143 ordinary shares. All share and per share data has been retrospectively presented. 

The
accompanying notes are an integral part of the unaudited financial statements.

2

DRUGS
MADE IN AMERICA ACQUISITION CORP.

STATEMENTS
OF CHANGES IN SHAREHOLDERS’ DEFICIT

(UNAUDITED)

FOR
THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025

    Ordinary
    Shares  
    Share
    Subscription  
    Additional
    Paid-in  
    Accumulated  
    Total
    Shareholders’